Our in vitro effects counsel that EAM-2201 ought to be examined concerning likely in vivo pharmacokinetic drug–drug interactions because of time-dependent inhibition of CYP2C8, CYP2C9, CYP2C19 and CYP3A4 activities and aggressive inhibition of UGT1A3 action. ED50 values have been deemed substantially different once the 95% confidence boundaries in the potency https://gailv616csi9.wiki-jp.com/user